546 related articles for article (PubMed ID: 25673718)
41. Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet.
Bonnafous P; Naesens L; Petrella S; Gautheret-Dejean A; Boutolleau D; Sougakoff W; Agut H
Antivir Ther; 2007; 12(6):877-88. PubMed ID: 17926642
[TBL] [Abstract][Full Text] [Related]
42. Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes.
Schubert A; Gentner E; Bohn K; Schwarz M; Mertens T; Sauerbrei A
Antiviral Res; 2014 Jul; 107():16-22. PubMed ID: 24747042
[TBL] [Abstract][Full Text] [Related]
43. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
[TBL] [Abstract][Full Text] [Related]
44. [A novel colorimetric test to study the susceptibility of human cytomegalovirus DNA polymerase to foscarnet].
Ducancelle A; Alain S; Scieux C; Fillet AM; Petit F; Sanson-Le Pors MJ; Mazeron MC
Pathol Biol (Paris); 2005; 53(8-9):551-5. PubMed ID: 16084026
[TBL] [Abstract][Full Text] [Related]
45. Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
Fischer L; Sampaio KL; Jahn G; Hamprecht K; Göhring K
J Clin Virol; 2015 Aug; 69():150-5. PubMed ID: 26209398
[TBL] [Abstract][Full Text] [Related]
46. Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children.
Wang Y; Wang Q; Zhu Q; Zhou R; Liu J; Peng T
J Clin Virol; 2011 Oct; 52(2):107-12. PubMed ID: 21778105
[TBL] [Abstract][Full Text] [Related]
47. Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in
Piret J; Goyette N; Boivin G
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807919
[TBL] [Abstract][Full Text] [Related]
48. Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2.
Sauerbrei A; Bohn K; Heim A; Hofmann J; Weissbrich B; Schnitzler P; Hoffmann D; Zell R; Jahn G; Wutzler P; Hamprecht K
Antivir Ther; 2011; 16(8):1297-308. PubMed ID: 22155911
[TBL] [Abstract][Full Text] [Related]
49. In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.
Piret J; Goyette N; Boivin G
Antiviral Res; 2022 Jun; 202():105328. PubMed ID: 35490740
[TBL] [Abstract][Full Text] [Related]
50. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Scott GM; Weinberg A; Rawlinson WD; Chou S
Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
[TBL] [Abstract][Full Text] [Related]
51. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
James SH; Price NB; Hartline CB; Lanier ER; Prichard MN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3321-5. PubMed ID: 23650158
[TBL] [Abstract][Full Text] [Related]
52. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus.
Chou S; Lurain NS; Thompson KD; Miner RC; Drew WL
J Infect Dis; 2003 Jul; 188(1):32-9. PubMed ID: 12825168
[TBL] [Abstract][Full Text] [Related]
53. Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art.
Campos AB; Ribeiro J; Boutolleau D; Sousa H
Rev Med Virol; 2016 May; 26(3):161-82. PubMed ID: 26990717
[TBL] [Abstract][Full Text] [Related]
54. Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility.
Brunnemann AK; Liermann K; Deinhardt-Emmer S; Maschkowitz G; Pohlmann A; Sodeik B; Fickenscher H; Sauerbrei A; Krumbholz A
Sci Rep; 2016 Jul; 6():29903. PubMed ID: 27426251
[TBL] [Abstract][Full Text] [Related]
55. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus.
Sauerbrei A; Deinhardt S; Zell R; Wutzler P
Antiviral Res; 2010 Jun; 86(3):246-52. PubMed ID: 20211650
[TBL] [Abstract][Full Text] [Related]
56. Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers.
Chen H; Lawler JL; Filman DJ; Hogle JM; Coen DM
mBio; 2021 Feb; 12(1):. PubMed ID: 33563814
[TBL] [Abstract][Full Text] [Related]
57. Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1.
Schalkwijk HH; Shewakramani NR; Das K; Andrei G; Snoeck R
Antimicrob Agents Chemother; 2024 May; 68(5):e0011024. PubMed ID: 38619252
[TBL] [Abstract][Full Text] [Related]
58. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy.
Chou S; Marousek G; Parenti DM; Gordon SM; LaVoy AG; Ross JG; Miner RC; Drew WL
J Infect Dis; 1998 Aug; 178(2):526-30. PubMed ID: 9697736
[TBL] [Abstract][Full Text] [Related]
59. Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance.
Shi R; Azzi A; Gilbert C; Boivin G; Lin SX
Proteins; 2006 Aug; 64(2):301-7. PubMed ID: 16705640
[TBL] [Abstract][Full Text] [Related]
60. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.
Burrel S; Deback C; Agut H; Boutolleau D
Antimicrob Agents Chemother; 2010 Nov; 54(11):4833-42. PubMed ID: 20733037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
